Volume : 11, Issue : 08, August – 2024
Title:
ALOPECIA: EXPLORING CONVENTIONAL TREATMENTS AND THE PROMISING POTENTIAL OF HERBAL MEDICINE
Authors :
Sumit Kumar Tantway* and Mukesh Patel
Abstract :
Hair, a vital component of the human body, originates from the skin’s ectoderm and acts as a protective appendage. It includes two types: terminal hair, which is dark and thick, and vellus. Hair growth follows three cyclical phases: anagen, catagen, and telogen. Typically, 50–100 hairs are shed daily; excessive loss leads to a condition known as alopecia. Alopecia, characterized by hair loss, affects millions worldwide and presents in various forms, each with distinct etiologies and clinical manifestations. The primary types include androgenetic alopecia, alopecia areata, telogen effluvium, and cicatricial alopecia. While numerous treatment options are available, ranging from topical applications like minoxidil and corticosteroids to systemic therapies such as finasteride and immunosuppressants, these often have limited efficacy and potential side effects. Therefore, the quest for more effective and safer treatments continues. Herbal medicine has emerged as a promising alternative, offering natural remedies with fewer side effects. Herbs such as ginseng, saw palmetto, rosemary, and peppermint essential oils have demonstrated potential in promoting hair growth and improving scalp health. These herbal treatments are valued for their holistic benefits and minimal adverse effects, making them an attractive option for many patients. Integrating herbal remedies with conventional therapies could provide a more comprehensive and personalized approach to managing alopecia. This review underscores the need for ongoing research into both conventional and herbal treatments to develop effective strategies for combating hair loss and improving patients’ quality of life.
Cite This Article:
Please cite this article in press Sumit Kumar Tantway et al., Alopecia: Exploring Conventional Treatments And The Promising Potential Of Herbal Medicine.,Indo Am. J. P. Sci, 2024; 11 (08).
Number of Downloads : 10
References:
1. http://www.drugs.com/hair-loss.html
2. http://www.follicle.com/hair-structure-life-cycle.html, accessed at 28/01/11
3. Brannon, Maryland, Heather. “Anagen Phase” The New York Times. Retrieved 2007-11-14.
4. Brannon, Maryland, Heather. “Categen Phase” The New York Times. Retrieved 2007-11-14.
5. Brannon, Maryland, Heather. “Telogen Phase” The New York Times. Retrieved 2007-11-14.
6. K. S. Stenn; R. Paus (January 1, 2001). “Controls of Hair Follicle Cycling” Physiological Reviews 81(1),2001, 449–494.
7. Nixon AJ, Ashby MG, Saywell DP, Pearson AJ. 1995. Seasonal fiber growth cycles of ferrets (Mustela putorious furo) and long-term effect of melatonin treatment. J Exp Zool 272:435–445.
8. Curlewis JD, Loudon ASI, Milne JA, McNeilly AS. 1988. Effects of chronic long-lasting bromocryptine treatment on liveweight voluntary food intake, coat growth, and breeding season in nonpregnant red deer hinds. J Endocrinol 119:413–420.
9. Tajima M, Hamada C, Takayuki A, Miyazawa M, Shibata R, Ishino A. 2007. Characteristic features of Japanese women’s hair with aging and with progressing hair loss. J Dermatol Sci 45:93–103.
10. Van Neste D. 2004. Thickness, medullation, and growth rate of female scalp hair are subject to significant variation according to pigmentation and scalp location during aging. Eur J Dermatol 14:28–32.
11. Horenstein VD-P, Williams LE, Brady AR, Abee CR, Horenstein MG. 2005. Age-related diffuse chronic telogen effluvium-type alopecia in female squirrel monkeys (Saimiri boliviensis boliviensis). Comp Med 55:169–174.
12. Huneke RB, Foltz CJ, VandeWoude S, Mandress TD, Garman RH. 1996. Characterization of dermatologic changes in geriatric rhesus macaques. J Med Primatol 25:404–413.
13. Rushton DH. 2002. Nutritional factors and hair loss. Clin Exp Dermatol 27:396–404.
14. Golub MS, Keen CL, Gershwin E, Styne DM, Takeuchi PT, Ontell F, Walter RM, Hendrickx AG. 1996. Adolescent growth and maturation in zinc-deprived rhesus monkeys. Am J Clin Nutr 64:274–282
15. Otberg N, Kang H, Alzolibani AA, Shapiro J. 2008. Folliculitis decalvans. Dermatol Ther 21:238–244.
16. Diani AR, Mills CJ. 1994. Immunocytochemical localization of androgen receptors in the scalp of the stumptail macaque monkey, a model of androgenetic alopecia. J Invest Dermatol 102:511–514.
17. Diani AR, Shull KL, Zaya MJ, Brunden MN. 1995. The penetration enhancer SEPA augments stimulation of scalp hair growth by topical minoxidil in the balding stumptail macaque. Skin Pharmacol 8:221–228.
18. Wiedemeyer K, Schill WB, Loser C. 2004. Diseases on hair follicles leading to hair loss, part I: nonscarring alopecias. Skinmed 3:209–214.
19. Beardi B, Wanert F, Zoller M, Freyschmidt-Paul P, Kaup F-J. 2007. Alopecia areata in a rhesus monkey (Macaca mulatta). J Med Primatol 36:124–130.
20. Eichberg JW, De Villez RL. 1984. Alopecia totalis in a chimpanzee. J Med Primatol 13:81–88.
21. Otberg N, Kang H, Alzolibani AA, Shapiro J. 2008. Folliculitis decalvans. Dermatol Ther 21:238–244.
22. Picardi A, Abeni D. 2001. Stressful life events and skin diseases: disentangling evidence from myth. Psychother Psychosom 70:118136.
23. Özdemir M, Balevi A. Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata. Pediatric Dermatology. 2017;34(2):128-132.
24. Sardana K, Gupta A, Gautam RK. Recalcitrant alopecia areata responsive to leflunomide and anthralin-Potentially undiscovered JAK/STAT inhibitors? Pediatr Dermatol. 2018;35(6):856-858.
25. Torchia D, Schachner LA. Bilateral Treatment for Alopecia Areata. Pediatric Dermatology. 2010;27(4):415-416.
26. Wu SZ, Wang S, Ratnaparkhi R, Bergfeld WF. Treatment of pediatric alopecia areata with anthralin: A retrospective study of 37 patients. Pediatr Dermatol. 2018;35(6):817-820.
27. Hull SM, Pepall L, Cunliffe WJ. Alopecia areata in children: response to treatment with 341 diphencyprone. Br J Dermatol. 1991;125(2):164-168.
28. Luk NM, Chiu LS, Lee KC, et al. Efficacy and safety of diphenylcyclopropenone among Chinese patients with steroid resistant and extensive alopecia areata. J Eur Acad Dermatol Venereol. 2013;27(3):e400-405.
29. Orecchia G, Rabbiosi G. Treatment of alopecia areata with diphencyprone. Dermatologica. 1985;171(3):193-196.
30. Salsberg JM, Donovan J. The safety and efficacy of diphencyprone for the treatment of alopecia areata in children. Arch Dermatol. 2012;148(9):1084-1085.
31. Schuttelaar ML, Hamstra JJ, Plinck EP, et al. Alopecia areata in children: treatment with diphencyprone. The British journal of dermatology. 1996;135(4):581-585.
32. Singh G, Okade R, Naik C, Dayanand CD. Diphenylcyclopropenone immunotherapy in ophiasis. Indian J Dermatol Venereol Leprol. 2007;73(6):432-433.
33. Sotiriadis D, Patsatsi A, Lazaridou E, Kastanis A, Vakirlis E, Chrysomallis F. Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata. Clin Exp Dermatol. 2007;32(1):48-51.
34. Wasylyszyn T, Borowska K. Possible advantage of imiquimod and diphenylcyclopropenone combined treatment versus diphenylcyclopropenone alone: An observational study of nonresponder patients with alopecia areata. The Australasian journal of dermatology. 2017;58(3):219-223.
35. Lee S, Kim BJ, Lee YB, Lee WS. Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis. JAMA Dermatol. 2018;154(10):1145-1151.
36. Giannetti A, Orecchia G. Clinical experience on the treatment of alopecia areata with squaric acid dibutyl ester. Dermatologica. 1983;167(5):280-282.
37. Chen CA, Carlberg V, Kroshinsky D. Angioedema After Squaric Acid Treatment in a 6-Year-Old Girl. Pediatr Dermatol. 2017;34(1):e44-e46.
38. Yun D, Silverberg NB, Stein SL. Alopecia areata treated with hydroxychloroquine: A retrospective study of nine pediatric cases. Pediatr Dermatol. 2018;35(3):361-365.
39. Lenane P, Pope E, Krafchik B. Congenital alopecia areata. Journal of the American Academy of Dermatology. 2005;52(2 Suppl 1):8-11.
40. Baral J. Minoxidil and Tail‐like Effect. International journal of dermatology. 1989;28(2):140-140.
41. Georgala S, Befon A, Maniatopoulou E, Georgala C. Topical Use of Minoxidil in Children and Systemic Side Effects. Dermatology. 2007;214(1):101-102.
42. Guerouaz N, Mohamed AO. Minoxidil induced hypertrichosis in children. The Pan African medical journal. 2014;18:8.
43. Herskovitz I, Freedman J, Tosti A. Minoxidil induced hypertrichosis in a 2 year-old child. F1000Res. 2013;2:226-226.
44. Rai AK. Minoxidil-Induced Hypertrichosis in a Child with Alopecia Areata. Indian Dermatol Online J. 2017;8(2):147-148
45. Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.
46. Thiers BH. Topical tacrolimus: treatment failure in a patient with alopecia areata. Archives of dermatology. 2000;136(1):124.
47. Price VH. Therapy of Alopecia Areata: On the Cusp and in the Future. Journal of Investigative Dermatology Symposium Proceedings. 2003;8(2):207-211
48. Montes LF. Topical halcinonide in alopecia areata and in alopecia totalis. Journal of cutaneous 412 pathology. 1977;4(2):47-50
49. Camacho FM, Garcia-Hernandez MJ. Zinc aspartate, biotin, and clobetasol propionate in the 414 treatment of alopecia areata in childhood. Pediatr Dermatol. 1999;16(4):336-338.
50. Lalosevic J, Gajic-Veljic M, Bonaci-Nikolic B, Nikolic M. Combined oral pulse and topical corticosteroid therapy for severe alopecia areata in children: a long-term follow-up study. Dermatologic therapy. 2015;28(5):309-317.
51. Borchert M, Bruce S, Wirta D, et al. An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects. Clin Ophthalmol. 2016;10:419-429.
52. Zaheri S, Hughes B. Successful use of bimatoprost in the treatment of alopecia of the eyelashes. Clin Exp Dermatol. 2010;35(4):e161-162.
53. Li AW, Antaya RJ. Successful Treatment of Pediatric Alopecia Areata of the Scalp Using Topical Bimatoprost. Pediatr Dermatol. 2016;33(5):e282-283.
54. Mehta JS, Raman J, Gupta N, Thoung D. Cutaneous latanoprost in the treatment of alopecia areata. Eye (London, England). 2003;17(3):444-446.
55. Yadav S, Dogra S, Kaur I. An unusual anatomical colocalization of alopecia areata and vitiligo in a child, and improvement during treatment with topical prostaglandin E2. Clin Exp Dermatol. 2009;34(8):e1010-1011.
56. Coronel-Pérez IM, Rodríguez-Rey EM, Camacho-Martínez FM. Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis. Journal of the European Academy of Dermatology and Venereology : JEADV. 2010;24(4):481-485
57. Gensure RC. Clinical response to combined therapy of cyclosporine and prednisone. J Investig Dermatol Symp Proc. 2013;16(1):S58.
58. Kim BJ, Uk min S, Park KY, et al. Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata. Journal of Dermatological Treatment. 2008;19(4):216-220.
59. Alabdulkareem AS, Abahussein AA, Okoro A. Severe alopecia areata treated with systemic corticosteroids. International Journal of Dermatology. 1998;37(8):622-624.
60. Schindler AM. The Boy Whose Hair Came Back. Hospital Practice. 1987;22(9):185-188.
61. Unger WP, Schemmer RJ. Corticosteroids in the treatment of alopecia totalis. Systemic effects. Archives of dermatology. 1978;114(10):1486-1490.
62. Winter RJ, Kern F, Blizzard RM. Prednisone therapy for alopecia areata. A follow-up report. Archives of dermatology. 1976;112(11):1549-1552
63. Chong JH, Taieb A, Morice-Picard F, Dutkiewicz AS, Leaute-Labreze C, Boralevi F. High-dose pulsed corticosteroid therapy combined with methotrexate for severe alopecia areata of childhood. Journal of the European Academy of Dermatology and Venereology : JEADV. 2017;31(11):e476-e477
64. Droitcourt C, Milpied B, Ezzedine K, et al. Interest of High-Dose Pulse Corticosteroid Therapy Combined with Methotrexate for Severe Alopecia Areata: A Retrospective Case Series. Dermatology. 2012;224(4):369-373.
65. Anuset D, Perceau G, Bernard P, Reguiai Z. Efficacy and Safety of Methotrexate Combined with Low- to Moderate-Dose Corticosteroids for Severe Alopecia Areata. Dermatology. 2016;232(2):242-248
66. Friedland R, Tal R, Lapidoth M, Zvulunov A, Ben Amitai D. Pulse corticosteroid therapy for alopecia areata in children: a retrospective study. Dermatology (Basel, Switzerland). 2013;227(1):37-44.
67. Michalowski R, Kuczynska L. Long-term intramuscular triamcinolon-acetonide therapy in alopecia areata totalis and universalis. Archives of dermatological research. 1978;261(1):73-76.
68. Shreberk-Hassidim R, Ramot Y, Gilula Z, Zlotogorski A. A systematic review of pulse steroid therapy for alopecia areata. Journal of the American Academy of Dermatology. 2016;74(2):372- 374.e375. 498 78.
69. Efentaki P, Altenburg A, Haerting J, Zouboulis CC. Medium-dose prednisolone pulse therapy in alopecia areata. Dermatoendocrinol. 2009;1(6):310-313.
70. Batalla A, Flórez Á, Abalde T, Vázquez-Veiga H. Methotrexate in Alopecia Areata: A Report of Three Cases. Int J Trichology. 2016;8(4):188-190.
71. Landis ET, Pichardo-Geisinger RO. Methotrexate for the treatment of pediatric alopecia areata. The Journal of dermatological treatment. 2018;29(2):145-148.
72. Lucas P, Bodemer C, Barbarot S, Vabres P, Royer M, Mazereeuw-Hautier J. Methotrexate in Severe Childhood Alopecia Areata: Long-term Follow-up. Acta Derm Venereol. 2016;96(1):102-103.
73. Royer M, Bodemer C, Vabres P, et al. Efficacy and tolerability of methotrexate in severe childhood alopecia areata. British Journal of Dermatology. 2011;165(2):407-410.
74. Mascia P, Milpied B, Darrigade AS, et al. Azathioprine in combination with methotrexate: a therapeutic alternative in severe and recalcitrant forms of alopecia areata? Journal of the European Academy of Dermatology and Venereology : JEADV. 2019.
75. Kiszewski AE, Bevilaqua M, De Abreu LB. Mesalazine in the Treatment of Extensive Alopecia Areata: A New Therapeutic Option? Int J Trichology. 2018;10(3):99-102.
76. Bakar O, Gurbuz O. Is there a role for sulfasalazine in the treatment of alopecia areata? Journal of the American Academy of Dermatology. 2007;57(4):703-706.
77. Rashidi T, Mahd AA. Treatment of persistent alopecia areata with sulfasalazine. International journal of dermatology. 2008;47(8):850-852.
78. Aghaei S. An uncontrolled, open label study of sulfasalazine in severe alopecia areata. Indian J Dermatol Venereol Leprol. 2008;74(6):611-613.
79. Guttman-Yassky E, Ungar B, Noda S, et al. Extensive alopecia areata is reversed by IL-12/IL 23p40 cytokine antagonism. The Journal of allergy and clinical immunology. 2016;137(1):301-304.
80. Aleisa A, Lim Y, Gordon S, et al. Response to ustekinumab in three pediatric patients with alopecia areata. Pediatr Dermatol. 2019;36(1):e44-e45.
81. Ortolan LS, Kim SR, Crotts S, et al. IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans. The Journal of allergy and clinical immunology. 2019.
82. Gilhar A, Keren A, Paus R. JAK inhibitors and alopecia areata. Lancet (London, England). 2019;393(10169):318-319.
83. www.clinicaltrials.gov.
84. Howell MD, Kuo FI, Smith PA. Targeting the Janus Kinase Family in Autoimmune Skin Diseases. Front Immunol. 2019;10:2342.
85. Jabbari A, Dai Z, Xing L, et al. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015;2(4):351-355.
86. Castelo-Soccio L. Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis. Journal of the American Academy of Dermatology. 2017;76(4):754-755.
87. Brown L, Skopit S. An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review. Journal of drugs in dermatology : JDD. 2018;17(8):914-917.
88. Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children. Journal of the American Academy of Dermatology. 2019;80(2):568-570.
89. Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. Journal of the American Academy of Dermatology. 2017;76(1):29-32.
90. Dai YX, Chen CC. Tofacitinib therapy for children with severe alopecia areata. Journal of the American Academy of Dermatology. 2019;80(4):1164-1166.
91. Patel NU, Oussedik E, Grammenos A, Pichardo-Geisinger R. A Case Report Highlighting the Effective Treatment of Alopecia Universalis With Tofacitinib in an Adolescent and Adult Patient. J Cutan Med Surg. 2018;22(4):439-442
92. Bayart CB, DeNiro KL, Brichta L, Craiglow BG, Sidbury R. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. Journal of the American Academy of Dermatology. 2017;77(1):167-170.
93. Craiglow BG, Tavares D, King BA. Topical Ruxolitinib for the Treatment of Alopecia Universalis. JAMA Dermatol. 2016;152(4):490-491.
94. Putterman E, Castelo-Soccio L. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. Journal of the American Academy of Dermatology. 2018;78(6):1207-1209.e1201.
95. Al-Mutairi N. 308-nm excimer laser for the treatment of alopecia areata. Dermatol Surg. 2007;33(12):1483-1487.
96. Al-Mutairi N. 308-nm excimer laser for the treatment of alopecia areata in children. Pediatr Dermatol. 2009;26(5):547-550.
97. Zakaria W, Passeron T, Ostovari N, Lacour JP, Ortonne JP. 308-nm excimer laser therapy in alopecia areata. Journal of the American Academy of Dermatology. 2004;51(5):837-838.
98. Fenniche S, Hammami H, Zaouak A. Association of khellin and 308-nm excimer lamp in the treatment of severe alopecia areata in a child. J Cosmet Laser Ther. 2018;20(3):156-158.
99. Lux-Battistelli C. Combination therapy with zinc gluconate and PUVA for alopecia areata totalis: an adjunctive but crucial role of zinc supplementation. Dermatologic therapy. 2015;28(4):235-238.
100. Yoon TY, Kim YG. Infant alopecia universalis: role of topical PUVA (psoralen ultraviolet A) radiation. International journal of dermatology. 2005;44(12):1065-1067.
101. Belezos NK. Local estrogen and ultraviolet irradiation in the treatment of total alopecia (areata). Dermatologica. 1965;131(4):304-308
102. Majumdar B, De A, Ghosh S, et al. “Turban PUVAsol:” A Simple, Novel, Effective, and Safe Treatment Option for Advanced and Refractory Cases of Alopecia Areata. Int J Trichology. 2018;10(3):124-128.
103. Jury CS, McHenry P, Burden AD, Lever R, Bilsland D. Narrowband ultraviolet B (UVB) phototherapy in children. Clin Exp Dermatol. 2006;31(2):196-199.
104. Mlacker S, Aldahan AS, Simmons BJ, et al. A review on laser and light-based therapies for alopecia areata. Journal of Cosmetic and Laser Therapy. 2017;19(2):93-99
105. Majumdar B, De A, Ghosh S, et al. “Turban PUVAsol:” A Simple, Novel, Effective, and Safe Treatment Option for Advanced and Refractory Cases of Alopecia Areata. International journal of trichology. 2018;10(3):124-128.
106. DK Singh; S Luqman; AK Mathur; L Lawsonia inermis. Ind Crops Prod. 2015, 65,269-86
107. N Adhirajan; T Ravikumar; N Shanmugasundram; M Babu. J. Ethanopharmacol, 2003, 88, 235-239.
108. N Adhirajan; VK Dixit; C Gowri., India Drugs, 2001, 38(11), 559-563.
109. SR Rho; JS Park; SL Hwang; IH Lee; SY Chang; MH Rang. J. Dermatol Sci, 2005, 38, 89-97.
110. LO Orafidiya; EO Agbani; KA Adelusola; EO Lwalewa; OA Adebanji; EAF Adediran, NT Agbani. Int. J. Aromather, 2004, 14(3), 119-128.
111. M Daniel. Medicinal Plants Chemistry and Properties, Oxford and IBH Co. Pvt. Ltd., New Delhi, 2006, 173.
112. Y Inaoka; M Fukushima; H Kuroda., Jap. Kokai Tokkyo Koho, 1988, 9.
113. M Daniel. Medicinal Plants Chemistry and Properties, Oxford and IBH Co. Pvt. Ltd., New Delhi, 2006, 92.
114. N Kobayashi; R Suzuki; C Koide; T Suzuki; H Matsuda; M Kubo. Yakugaku Zasshi, 1993, 113, 718-724.
115. A Mohammad; R Earla; R Ramidi. Fitoterapia, 2001, 72(3), 313-315.
116. HO Edeoga; DE Okwu; BO Mbaebie. J. Biotechnol., 2005, 4(7), 685-688.
117. The Wealth of India, Vol – X, CSIR, New Delhi, 1976, 292.
118. S Saraf; AK Pathak; VK Dixit. Fitoterapia, 1991, 62, 495-498.
119. http://www.mdidea.com/products/herbs extrat/sophoraal/data.html.
120. SS Roh; CD Kim; MH Lee; SL Hwang; MJ Rang; YK Yoon. J. Dermatol. Sci, 2002, 30, 43-49.
121. LD Kapoor, L. D., Handbook of Ayurvedic Medicinal Plants, CRC. Press, LLC, 1990, 122-123.
122. RKRoy; M Thakur; VK Dixit. J Cosmet Dermatol, 2007, 6, 108-112.
123. LD Kapoor, L. D., Handbook of Ayurvedic Medicinal Plants, CRC. Press, LLC, 1940, 175-176.
124. P Lipi; BN Suryaprakash; MS Pande. E- J. Chem., 2008, 5(1), 34-38.
125. LD Kapoor, L. D., Handbook of Ayurvedic Medicinal Plants, CRC. Press, LLC, 1990, 239.
126. EM Williamsom. Major Herbs of Ayurveda, Churchill Livingstone, London, 2002, 126-128.
127. RK Roy; M Thakur; VK Dixit. Arch Dermatol Res, 2008, 300, 357-364.
128. Khare CP. Encyclopedia of Indian medicinal plants. NewYork: Springes-Verlag Berlin Heidelberg. 2004.
129. V Rathi; JC Rathi; S Tamizharasia; AK Pathakb. Pharmacogn Rev, 2008, 2(3), 185-187.